Accelerate Diagnostics presents performance data at ECCMID
June 2022—Accelerate Diagnostics announced the release of new performance data on the Accelerate Arc module and blood culture kit.
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
Bio-Rad introduces anti-cemiplimab antibodies
June 2022—Bio-Rad Laboratories introduced a range of antibodies specific to cemiplimab (Libtayo) that inhibit the binding of the drug to its target, human programmed death receptor-1. The ready-made antibodies are suitable for developing selective and sensitive assays for the bioanalysis and drug monitoring of cemiplimab.
Siemens gets breakthrough device designation for sNfL assay
June 2022—Siemens Healthineers announced the FDA has granted breakthrough device designation for the Advia Centaur serum neurofilament light chain (sNfL) assay, developed in collaboration with Novartis Pharma. The assay quantitatively measures NfL in human serum and plasma and is intended to be used in conjunction with clinical, imaging, and laboratory findings as an aid in identifying adult patients with relapsing multiple sclerosis who are at lower risk, versus higher risk, of multiple sclerosis disease activity.
MSKCC awards GRM storage, management contract
June 2022—Memorial Sloan Kettering Cancer Center has awarded GRM Information Management a multiyear contract to store and manage pathology blocks and slides for the hospital’s clinical and research departments.
NxTAG gastrointestinal panel gets CE mark
June 2022—DiaSorin announced that Luminex, a DiaSorin company, CE marked its xMAP NxTAG Gastrointestinal Pathogen Panel (GPP). The new panel is a multiplex test that detects nucleic acids from 16 clinically relevant bacterial, viral, and parasitic pathogens in stool samples on the Magpix system.
ZeptoMetrix NATtrol SARS-CoV-2 omicron control
June 2022—ZeptoMetrix announced the release of its NATtrol SARS-CoV-2 Omicron External Run Control, for research use only, to evaluate the performance of nucleic acid tests for determining the presence of SARS-CoV-2 omicron variant RNA. The control is formulated with purified, intact organisms and is for use with a real-time PCR thermal cycler. The product is available in six 0.5-mL vials and is refrigerator stable at 2° to 8°C.
Tribun Health enters pharmaceutical market
June 2022—Tribun Health announced its expansion into the pharmaceutical market with the appointment of Loic Dartois as vice president of pharma. Dartois joined Tribun Health in March and is developing commercial offerings for the pharma industry. “Digital pathology data combined with best-in-class AI models has the power to improve treatments’ responses to a better targeted population,” Dartois said in a press release. “Thanks to its growing footprint in health care institutions in Europe and North America, Tribun Health is best positioned to support the pharmaceutical industry in its precision medicine transformation using an industry-leading digital pathology platform and deploying a thought leadership AI team.”
Sysmex America to distribute Exbio antibodies
June 2020—Sysmex America has expanded its reagent portfolio by becoming a distributor of more than 450 Exbio single-color antibodies, cell stains, and buffering solutions. The company offers a comprehensive variety of analyte-specific reagent and research use only antibodies for immunophenotyping, cell staining and processing, and vitality assays, as well as for other research applications.
PreciseDx AI-enabled digital pathology detects Parkinson’s disease
June 2022—PreciseDx announced its AI-enabled digital pathology technology can accurately diagnose Parkinson’s disease in patients prior to severe onset of symptoms.
CE-marked Nova Max Pro creatinine/eGFR meter launched in EU
June 2022—Nova Biomedical launched the CE-marked Nova Max Pro creatinine/eGFR meter system in the EU market. Nova Max Pro is designed to improve kidney care through kidney function screening and early detection of kidney disease in point-of-care settings outside the hospital. The meter and creatinine biosensor measure blood creatinine and calculate estimated glomerular filtration rate from a 1.2-μL capillary fingerstick blood sample in 30 seconds. The measuring technology is based on the Nova StatSensor Creatinine technology.